Margolin, David H.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 1,205

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 1,198

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 277

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 221

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

Daniels, G. H., Vladic, A., Brinar, V., Zavalishin, I., Valente, W., Oyuela, P., Palmer, J., & Margolin, D. H. (2014) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsMultiple Sclerosis Research Studies

Cited by 150